UCB SA, a biopharmaceutical company, dedicates to the development of innovative medicines and solutions for patients with severe disease. The company’s primary business is rooted in identifying and addressing unmet medical needs, focusing primarily o…
Analysis
Hope premium
UCB SA is priced well ahead of what the underlying numbers justify, a pattern we describe as a hope premium.
On valuation, the picture is expensive. The owner-earnings multiple stands at 26.7×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 10% a year, against analyst forecasts of 19%. The price, in other words, assumes less than the experts do.
Growth is solid; the safety picture is sturdy. The company scores 20/20 on our value-creation score: strong value creator.
No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.
360° rank · history
1007550250
Jan 202330
83
2023202420252026
All-time high
83
Jun 2026
All-time low
29
Aug 2024
Average rank
55
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
37
11
46
54
Price/Earnings
26
15
54
71
Price/Book
48
21
81
78
Dividend Yield
45
32
49
61
Value (overall)
35
22
17
63
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.